PURPOSE To investigate a rationale of pancreatobiliary cancers, thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) concentrations in cancer tissues were evaluated. PATIENTS AND METHODS Twenty-nine patients with pancreatic cancer (PC) and 43 with biliary tract cancer (BTC; 27 cases of bile duct cancer, 8 of gallbladder cancer and 8 of cancer of the papillary area) were include...

Dihydropyrimidine dehydrogenase (DPD) is the initial, rate-limiting enzyme in the catabolism of 5-fluorouracil, one of the most widely used cancer chemotherapeutic agents. Previous studies have demonstrated the clinical importance of determination of DPD in cancer patients, suggesting that the efficacy and toxicity of 5-fluorouracil may directly relate to the DPD activity in both tumor and host...

Dihydropyrimidine dehydrogenase (DPD) is the initial key enzyme in the catabolism of 5-fluorouracil (5-FU). We measured DPD activity in lymphocytes from 57 consecutive head and neck cancer patients while simultaneously monitoring 5-FU pharmacokinetics during 5-day, continuous infusion (1000 mg/m2/day) 5-FU therapy (82 cycles in total). The mean value for DPD activity was 0.186 +/- 0.068 (SD) nm...

BACKGROUND The enzyme dihydropyrimidine dehydrogenase (DPD) is involved in the metabolism of 5-fluorouracil (5-FU). The aim of this study was to clarify the correlation between the expression of DPD and the efficacy of 5-FU therapy in patients with lung adenocarcinoma (AD). PATIENTS AND METHODS We examined surgically resected specimens from 90 stage I to IIIA patients with lung ADs to determi...

PURPOSE Complete or partial loss of dihydropyrimidine dehydrogenase (DPD) function has been described in cancer patients with intolerance to fluoropyrimidine drugs like 5-fluorouracil (5-FU) or Xeloda. The intention of this population study is to assess and to evaluate gene variations in the entire coding region of the dihydropyrimidine dehydrogenase gene (DPYD), which could be implicated in DP...

Purpose:Dihydropyrimidine dehydrogenase (DPD) deficiency is critical in the predisposition to 5-fluorouracil dose-related toxicity. We recently characterized the phenotypic [2-C]uracil breath test (UraBT) with 96% specificity and100% sensitivity for identification of DPD deficiency. In the present study, we characterize the relationships among UraBT-associated breath CO2 metabolite formation, p...

In this article, we propose a new behavioral modeling method to reduce the running complexity and power consumption of digital predistortion (DPD) models for radio frequency amplifiers. By employing proposed method, different cross terms in DPD model can be switched dynamically real time. Each cross-term branch further choose coefficients from multiple coefficient sets, which improves performan...

Dihydropyrimidine dehydrogenase (DPD) is the mitial, rate-limiting enzyme in the catabolism of 5-fluorou. racil, one of the most widely used cancer chemotherapeutic agents. Previous studies have demonstrated the clinical importance of determination of DPD in cancer patients, suggesting that the efficacy and toxicity of 5-fluorouracil may directly relate to the DPD activity in both tumor and hos...

Power amplifier (PA) efficiency and linearity are among the key drivers to reduce energy consumption while enabling high data rates in fifth-generation (5G) millimeter-wave phased array transmitters. Analog per-branch phase amplitude control is used steer beam, suppress sidelobes, form zeros desired spatial directions. The of individual PA inputs makes nonlinearity vary from antenna antenna, wh...

Expression of dihydropyrimidine dehydrogenase (DPD) displays a regular daily oscillation in nonmalignant cells. In colorectal cancer cells, the expression of this 5-fluorouracil-metabolizing enzyme is decreased, but the reason remains unclear. In this study, we analyzed by real-time reverse transcription-PCR (RT-PCR) the expression of DPD and of members of the cellular oscillation machinery, pe...